Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (Solid Biosciences)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Kinea Bio for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.
Solid Biosciences Shares Updates on Inspire Duchenne Clinical Trial of SGT-003
Solid Biosciences, a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, shared updates on the INSPIRE DUCHENNE clinical trial for their next-generation AAV micro-dystrophin gene therapy candidate, SGT-003, for the treatment of Duchenne.
UF Team Plays Major Role in Success of Newly Approved Duchenne Muscular Dystrophy Drug
Duchenne muscular dystrophy families, advocates and healthcare providers celebrated a milestone in March with the U.S. Food and Drug Administration’s approval of the first nonsteroidal drug for the treatment of Duchenne. The University of Florida’s expertise in magnetic resonance imaging provided objective, measurable results in the drug’s clinical trials.